| Literature DB >> 31960055 |
Fabian L Cardenas-Diaz1,2, Karla F Leavens3, Siddharth Kishore1,4, Catherine Osorio-Quintero1, Yi-Ju Chen4, Ben Z Stanger4,5, Pei Wang6, Deborah French1, Paul Gadue1.
Abstract
Human in vitro model systems of diabetes are critical to both study disease pathophysiology and offer a platform for drug testing. We have generated a set of tools in the human β-cell line EndoC-βH1 that allows the efficient and inexpensive characterization of β-cell physiology and phenotypes driven by disruption of candidate genes. First, we generated a dual reporter line that expresses a preproinsulin-luciferase fusion protein along with GCaMP6s. This reporter line allows the quantification of insulin secretion by measuring luciferase activity and calcium flux, a critical signaling step required for insulin secretion, via fluorescence microscopy. Using these tools, we demonstrate that the generation of the reporter human β-cell line was highly efficient and validated that luciferase activity could accurately reflect insulin secretion. Second, we used a lentiviral vector carrying the CRISPR-Cas9 system to generate candidate gene disruptions in the reporter line. We also show that we can achieve gene disruption in ~90% of cells using a CRISPR-Cas9 lentiviral system. As a proof of principle, we disrupt the β-cell master regulator, PDX1, and show that mutant EndoC-βH1 cells display impaired calcium responses and fail to secrete insulin when stimulated with high glucose. Furthermore, we show that PDX1 mutant EndoC-βH1 cells exhibit decreased expression of the β-cell-specific genes MAFA and NKX6.1 and increased GCG expression. The system presented here provides a platform to quickly and easily test β-cell functionality in wildtype and cells lacking a gene of interest. © Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.Entities:
Keywords: CRISPR/Cas9 gene editing; beta-cell physiology; calcium imaging; diabetes; disease modeling; insulin secretion
Mesh:
Substances:
Year: 2020 PMID: 31960055 PMCID: PMC7028009 DOI: 10.1210/endocr/bqaa005
Source DB: PubMed Journal: Endocrinology ISSN: 0013-7227 Impact factor: 4.736